ACAD Stock Risk & Deep Value Analysis
ACADIA Pharmaceuticals Inc
DVR Score
out of 10
What You Need to Know About ACAD Stock
We analyzed ACADIA Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ACAD through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
ACAD Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is the failure of NUPLAZID in Alzheimer's Disease Psychosis (ADP) clinical trials or its eventual regulatory rejection. As the primary driver for a 10x growth scenario, a setback here would significantly devalue the company, potentially leading to a 50%+ stock price decline and derailing long-term growth ambitions.
Risk Matrix
Overall
Aggressive
Financial
Medium
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
High
Red Flags
- ⚠
European Medicines Agency (EMA) issued negative opinion on trofinetide (DAYBUE) MAA for Rett syndrome, limiting international growth.
- ⚠
High reliance on NUPLAZID for ADP as the major 10x catalyst, which carries inherent high clinical failure risk in CNS disorders.
- ⚠
Head of R&D (Elizabeth H.Z. Thompson, Ph.D.) announced planned retirement by year-end 2026, creating potential transition uncertainty.
Upcoming Risk Events
- 📅
Negative clinical trial results for NUPLAZID in Alzheimer's Disease Psychosis
- 📅
Further regulatory setbacks for pipeline assets or international expansion attempts
- 📅
Increased competitive pressure in existing markets
When to Reconsider
- 🚪
Exit if NUPLAZID's Alzheimer's Disease Psychosis clinical trials report negative efficacy or safety data.
- 🚪
Sell if DAYBUE sales significantly underperform expectations or show sustained quarter-over-quarter decline.
- 🚪
Re-evaluate if the company begins to burn cash again without a clear pathway to profitability, necessitating dilutive financing.
Unlock ACAD Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
ACADIA Pharmaceuticals is a high-risk, high-reward investment leveraging two commercial drugs: DAYBUE (Rett Syndrome) for a stable base, and NUPLAZID (Parkinson's Disease Psychosis with significant Alzheimer's Disease Psychosis expansion potential). The company is profitable with improving financials. The 10x growth hinges almost entirely on NUPLAZID's success in ADP, a massive unmet market. While the EU rejection for DAYBUE's international expansion is a setback, the domestic market for both drugs, coupled with NUPLAZID's blockbuster potential, could still drive significant returns if clinical and regulatory hurdles are overcome.
Is ACAD Stock Undervalued?
Unlock the full AI analysis for ACAD
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
ACAD Price Targets & Strategy
12-Month Target
$29.00
Bull Case
$45.00
Bear Case
$15.00
Valuation Basis
Based on 16x forward P/E applied to estimated FY2026 EPS of $1.80, adjusted for pipeline potential.
Entry Strategy
Consider dollar-cost averaging in the $20-$22 range, near recent support levels, especially if there are further dips unrelated to NUPLAZID's clinical progress. Avoid aggressive buys before NUPLAZID ADP data readouts.
Exit Strategy
Take partial profits at $35 and $45. Implement a stop-loss order if the price falls below $18, particularly on adverse news regarding NUPLAZID or DAYBUE sales.
Portfolio Allocation
5% for aggressive risk tolerance, given the binary nature of NUPLAZID's potential impact.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is ACAD Financially Healthy?
Valuation
P/E Ratio
9.84
Forward P/E
15.56
EV/EBITDA
33.25
Price/Sales
3.39
Profitability
Gross Margin
91.71%
Operating Margin
10.34%
Net Margin
44.97%
Return on Equity
41.90%
Revenue Growth
-13.64%
EPS
$2.28
Balance Sheet
Current Ratio
3.83
Quick Ratio
3.49
Debt/Equity
0.07
Total Debt
$52.19M
Cash & Equivalents
$819.69M
Cash Flow
Operating Cash Flow
$187.91M
Free Cash Flow
$187.09M
EBITDA
$103.97M
Other
Beta (Volatility)
0.88
Does ACAD Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable to slightly eroding due to the EU regulatory setback for trofinetide, which limits geographic expansion of an existing asset's moat.
Moat Sources
2 Identified
The moat is primarily driven by intellectual property and regulatory exclusivities, which have defined lifespans. Long-term durability hinges on successfully developing and commercializing new, innovative therapies to replenish the pipeline and extend patent protection.
Moat Erosion Risks
- •Expiration of key drug patents, leading to generic competition.
- •Emergence of superior or more cost-effective treatments from competitors.
- •Increased regulatory hurdles or unfavorable policy changes impacting drug approval and pricing.
ACAD Competitive Moat Analysis
Sign up to see competitive advantages
ACAD Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral, with discussions likely focused on upcoming earnings and NUPLAZID trial progress.
Institutional Sentiment
Positive, with 96.7% institutional ownership. However, BofA Securities upgraded to Buy but lowered its price target from $31 to $29 due to pipeline/EU review, indicating tempered optimism.
Insider Activity (Form 4)
CFO Mark C. Schneyer sold 2,709 shares ($60,139.80) on April 7, 2026, to reduce ownership by 4.13%. Principal Accounting Officer James Kihara sold 1,030 shares on April 7, 2026, for RSU vesting taxes.
Options Flow
Normal options activity, with no specific unusual put/call ratios or block trades mentioned in the research.
Earnings Intelligence
Next Earnings
2026-05-06 (after market close)
Surprise Probability
Medium (Q4 2025 beat estimates significantly, but Q1 2026 consensus EPS of $0.06 is substantially lower, potentially setting a low bar for a beat, or reflecting increased R&D spend).
Historical Earnings Pattern
Based on limited recent data, the company generally shows positive surprise on earnings (Q4 2025 beat on both revenue and EPS), which could lead to positive stock reactions, though past performance does not guarantee future results.
Key Metrics to Watch
Competitive Position
Top Competitor
Biogen (BIIB)
Market Share Trend
Gaining market share/adoption for DAYBUE in the US with the STIX launch, but losing potential market share opportunity in Europe for trofinetide due to regulatory rejection.
Valuation vs Peers
Trading at a significant discount to many growth-oriented biotech peers on trailing P/E (~9.65), potentially reflecting the binary risk of NUPLAZID and recent EU setback, or indicating undervaluation if pipeline succeeds.
Competitive Advantages
- •Proprietary drugs with regulatory exclusivity (DAYBUE orphan drug status).
- •Established commercial infrastructure and expertise in CNS disorders.
- •Pipeline focused on areas of high unmet medical need (e.g., Alzheimer's Disease Psychosis).
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive ACAD Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report on May 6, 2026
- •Continued adoption and sales growth of DAYBUE STIX in the US
Medium-Term (6-18 months)
- •Clinical trial updates or data readouts for NUPLAZID in Alzheimer's Disease Psychosis
- •Potential strategic partnerships or pipeline advancements beyond current assets
Long-Term (18+ months)
- •FDA approval and successful commercial launch of NUPLAZID for Alzheimer's Disease Psychosis
- •Expansion into new therapeutic areas through R&D or acquisitions
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ACAD?
- ✓
Positive clinical trial data for NUPLAZID in Alzheimer's Disease Psychosis (ADP).
- ✓
Consistent growth in DAYBUE and NUPLAZID sales and improving profitability margins.
- ✓
Successful integration of new R&D leadership following Dr. Thompson's retirement.
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How ACADIA Pharmaceuticals Inc Makes Money
ACADIA Pharmaceuticals is a biopharmaceutical company that specializes in developing and commercializing innovative therapies for central nervous system (CNS) disorders and rare diseases. The company generates its revenue primarily from the sales of two FDA-approved drugs: NUPLAZID (pimavanserin) for Parkinson's Disease Psychosis, and DAYBUE (trofinetide) for Rett Syndrome. Their business model involves extensive research and development to identify and advance promising drug candidates through clinical trials, obtain regulatory approvals, and then commercialize these medicines through a dedicated sales and marketing infrastructure aimed at healthcare providers and patients.
Read Full Business Model BreakdownFAQ
What is the DVR Score for ACADIA Pharmaceuticals Inc (ACAD)?
As of April 30, 2026, ACADIA Pharmaceuticals Inc has a DVR Score of 6.6 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of ACADIA Pharmaceuticals Inc?
ACADIA Pharmaceuticals Inc's market capitalization is approximately $3.8B..
What is the risk level for ACAD stock?
Our analysis rates ACADIA Pharmaceuticals Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of ACAD?
ACADIA Pharmaceuticals Inc currently has a price-to-earnings (P/E) ratio of 9.8. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is ACADIA Pharmaceuticals Inc's revenue growing?
ACADIA Pharmaceuticals Inc has reported revenue growth of -13.6%. Revenue has been declining, which warrants closer examination.
Is ACAD stock profitable?
ACADIA Pharmaceuticals Inc has a profit margin of 45.0%. This indicates strong profitability.
How often is the ACAD DVR analysis updated?
Our AI-powered analysis of ACADIA Pharmaceuticals Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 30, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ACAD (ACADIA Pharmaceuticals Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.